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ARTICLE
Human substance P receptor binding mode of the
antagonist drug aprepitant by NMR and
crystallography
Shuanghong Chen1,2,3, Mengjie Lu1,2,3, Dongsheng Liu4, Lingyun Yang4, Cuiying Yi1,2, Limin Ma1,2, Hui Zhang1,2,3,
Qing Liu 2,5, Thomas M. Frimurer 6, Ming-Wei Wang 2,3,5,7,8, Thue W. Schwartz6,
Raymond C. Stevens 4,8, Beili Wu 2,3,8,9, Kurt Wüthrich4,8,10 & Qiang Zhao1,2,3,9
Neurokinin 1 receptor (NK1R) has key regulating functions in the central and peripheral
nervous systems, and NK1R antagonists such as aprepitant have been approved for treating
chemotherapy-induced nausea and vomiting. However, the lack of data on NK1R structure
and biochemistry has limited further drug development targeting this receptor. Here, we
combine NMR spectroscopy and X-ray crystallography to provide dynamic and static char-
acterisation of the binding mode of aprepitant in complexes with human NK1R variants. 19F-
NMR showed a slow off-rate in the binding site, where aprepitant occupies multiple substates
that exchange with frequencies in the millisecond range. The environment of the bound
ligand is affected by the amino acid in position 2.50, which plays a key role in ligand binding
and receptor signaling in class A GPCRs. Crystal structures now reveal how receptor signaling
relates to the conformation of the conserved NP7.50xxY motif in transmembrane helix VII.
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Substance P (SP) was the ﬁrst identiﬁed mammalian neu-ropeptide, which was discovered in 1931 by Von Euler andGaddum as a vasodilator substance in crude tissue extracts
from equine brain and intestine1. The acid alcohol extracted
powder was at the time referred to as SP (P for powder) and
eventually identiﬁed as an undecapeptide in 19712. The receptor
of SP, which was later named neurokinin 1 receptor (NK1R) or
tachykinin 1 receptor (TACR1), is widely distributed in the
central and peripheral nervous systems3, and is critically involved
in pain4, depression5, inﬂammatory and immune responses6,
neurodegenerative diseases3, cancer7 and emesis8. NK1R evokes
the release of many neurotransmitters such as acetylcholine,
GABA, catecholamine, and histamine9. Therefore, this receptor
has long been considered as an attractive drug target for the
treatment of pain, addiction, anxiety, and related disorders.
Aprepitant (2-(R)-(1-(R)-3,5-Bis(triﬂuoromethyl)phenylethoxy)-
3-(S)-(4-ﬂuoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpho-
line; also known as MK-869 and L-754030; Merck & Co., West
Point, Pennsylvania), is a highly selective NK1R antagonist. It is an
FDA-approved drug (brand name: Emend) for the treatment of
chemotherapy-induced nausea and vomiting (CINV)10,11, and
several related analogs have undergone clinical trials for depres-
sion12. Although these trials failed, potentially due to low receptor
occupancy, both preclinical data and positive clinical evidence
suggest that NK1R antagonists, including aprepitant, have a very
distinct therapeutic action with only mild and tolerable side-effects
when compared with all other antidepressants5,12,13. However, long
after its approval in 2003, the binding mechanism of aprepitant to
NK1R remains elusive due to a lack of structural information and
poor understanding of the receptor biology, limiting the develop-
ment of improved NK1R antagonists.
It was reported that mutations of NK1R at residue 2.50 (resi-
due numbering using Ballesteros–Weinstein nomenclature14),
which in class A G protein-coupled receptors (GPCRs) is highly
conserved as D2.50 or E2.50, greatly affects its agonist binding,
activation and downstream signaling15–17. These studies showed
that upon binding to SP, the wild-type NK1R efﬁciently activates
the Gs, Gq, and β-arrestin pathways. However, it has been
reported that mutating the conserved E2.50 to aspartic acid in
NK1R reduces the Gs and β-arrestin signaling with Gq signaling
unaffected17. Mutating this residue to asparagine in other GPCRs
also exhibited diminished signal transduction18,19. Overall, the
residue at position 2.50 of class A GPCRs is widely believed to
play a crucial role in GPCR activation20. It has also been postu-
lated that an extended hydrogen-bonding network between the
conserved residues in the 7-transmembrane (7TM) helical bundle
constitutes an allosteric interface essential for stabilizing different
active and inactive conformations17.
To provide static characterization of cognate ligand recognition
by NK1R and modulation of ligand binding by the residue in
position 2.50, we determined the crystal structures of two human
NK1R variants, with aspartic acid or asparagine at the 2.50
position, bound to the antagonist aprepitant. For understanding
the dynamic component of aprepitant binding, we conducted
nuclear magnetic resonance (NMR) spectroscopy of NK1R and
several functionally characterized variants.
Results
Overall architecture of NK1R. To improve receptor stability and
facilitate crystallization, three mutations, Y1213.41W, Q1654.60A,
and T2225.64R, were introduced and 10 residues (residues
227–236 of NK1R) of the third intracellular loop (ICL3) were
replaced with a modiﬁed T4 lysozyme (mini-T4L). The optimized
NK1R protein was co-crystallized with aprepitant, but the crystals
diffracted to only about 6 Å. The resolution was improved to 3.2
Å by replacing residue E782.50 with aspartic acid. To further
improve the crystal quality, the residue at the 2.50 position was
mutated to asparagine and Q1654.60A was reinstated, whereas
Y1213.41W and T2225.64R were maintained. The resulting
NK1R–aprepitant complex structure was determined at 2.7 Å
resolution (Supplementary Table 1). The two structures are
similar, with an overall Cα root mean square deviation (r.m.s.d.)
of 0.4 Å. The higher resolution structure was used in the dis-
cussion below.
The NK1R structure consists of a canonical 7TM helical bundle
with three extracellular loops (ECL1–3), three intracellular loops
(ICL1–3), and an amphipathic helix VIII (Fig. 1a). ECL2 forms a
β-hairpin structure with a conventional disulﬁde bond between
ECL2 and helix III, a feature also observed in other solved
structures of peptide GPCRs. Compared with the previously
determined crystal structure of the closely related neurotensin
receptor (NTSR1)21, the extracellular tips of helices I, V, VI and
VII move away from the central axis of the helix bundle by 3–5 Å
(Fig. 1b). These conformational differences on the extracellular
side are further transferred to the intracellular side of the helical
bundle (Fig. 1c). The intracellular tip of helix VI in the NK1R
structure moves inwards by 7 Å, while the tip of helix VII moves
outwards by 6 Å compared to the NTSR1 structure, which adopts
an active conformation. Since these structural differences were
not likely induced by the fusion partner differences between the
two structures22, our data suggest that the NK1R–aprepitant
structure is in an inactive state.
Ligand-binding pocket of aprepitant. Aprepitant is a derivative
of morpholine with bis-triﬂuomethyl-phenylethoxy, 4-ﬂuoro-
phenyl, and 3-oxo-triazol groups at its 2, 3, and 4 positions,
respectively10. It occupies a binding site in NK1R similar to that
of suvorexant in the orexin 2 receptor (OX2R) structure23,
adopting an extended conformation with the bis-triﬂuomethyl-
phenylethoxy group at the bottom of the binding pocket, the
morpholine and 4-ﬂuoro-phenyl groups in the middle, and the 3-
oxo-triazol group close to the extracellular surface (Fig. 2 and
Supplementary Figure 1a, b).
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Fig. 1 Overall structure of the NK1R–aprepitant complex. a Structure of the
NK1R–aprepitant complex. The NK1R structure is shown as green cartoon.
Aprepitant is shown as spheres with orange carbons. The disulﬁde bond is
displayed as yellow sticks. The missing portion of ICL3 is indicated by a
green dashed line. b, c Structural comparison between NK1R and NTSR1
(PDB accession code: 4GRV). The helical bundles of the receptors are
colored green (NK1R) and purple (NTSR1). b Extracellular view. c
Intracellular view
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Multiple hydrogen bonds as well as hydrophobic interactions
between NK1R and aprepitant are formed to ensure both ligand
selectivity and binding afﬁnity. The bis-triﬂuomethyl-phenyl is a
common chemical group shared by many different NK1R
antagonists. In the NK1R–aprepitant complex structure, it inserts
into a hydrophobic subpocket formed by helices III, V, and VI,
and serves as an anchor to stabilize the morpholine group in an
optimal orientation (Fig. 2a). Together with the benzene ring, the
two triﬂuomethyl groups pinch W2616.48 and inhibit the
activation of NK1R by preventing the toggle switch24 of this
residue. F2646.51 and P1123.32 form extensive interactions with
both triﬂuomethyl groups as well as edge-π interactions with the
benzene ring on either side. Additionally, the triﬂuomethyl
groups make hydrophobic contacts with I1133.33, V1163.36, and
I2045.46. These interactions serve to ﬁx aprepitant in the binding
pocket while mutations of the key residues greatly weaken the
antagonism activity of aprepitant (Supplementary Table 2).
The bis(triﬂuomethyl)phenylethoxy-morpholine-(4-ﬂuoro)
phenyl group adopts a horseshoe shape conformation with the
(4-ﬂuoro)phenyl group extending into a subpocket shaped by
helices V and VI in the NK1R structure, and the triazolinone
group makes strong interactions with helices IV and V and ECL2
(Fig. 2a). The nitrogen atoms in the triazole group form two
hydrogen bonds with Q1654.60, while the oxygen in the
triazolinone group establishes another two hydrogen bonds with
W184ECL2 and E1935.35. These hydrogen bonds greatly con-
tribute to the binding of aprepitant to the receptor, as shown in
Supplementary Table 2 and supported by previous studies where
removing the triazolinone substituent decreased ligand-binding
afﬁnity by 30-fold10,25.
Structural and signaling differences between 2.50 mutants. The
overall backbones of NK1R in the two crystal structures are very
similar (Cα r.m.s.d. within the whole receptor is 0.4 Å). However,
relatively large conformational differences of residue side chains
were observed around the 2.50 residue (Supplementary Figure 1c,
d). It has been reported that some conserved residues around this
region form a hydrogen-bond network to regulate receptor acti-
vation17. In the NK1R structure with the E782.50D mutation,
residue D782.50 forms a hydrogen bond with N3017.49 (2.8 Å). In
contrast, in the structure with the E782.50N mutant, the side chain
of N782.50 rotates by ~30°, eliminating the interaction between
N782.50 and N3017.49 (3.5 Å) (Fig. 3a). Without the hydrogen
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Fig. 2 The NK1R binding pocket for aprepitant. a Key residues of NK1R for aprepitant binding. The receptor is shown as gray cartoon. Aprepitant (orange
carbons) and receptor residues (green carbons) involved in ligand binding are shown as sticks. Other elements are colored as follows: oxygen, red;
nitrogen, dark blue; ﬂuorine, cyan. b Schematic representation of interactions between NK1R and aprepitant analyzed using the LigPlot+ program42. Polar
interactions are shown as dashed lines. c, d Comparison of ligand-binding sites between NK1R (green) and OX2R (PDB accession code: 4S0V; purple). The
ligands aprepitant and suvorexant are shown as orange and magenta sticks, respectively. c Extracellular view. d Side view
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bond, the main-chain backbone of the NP7.50xxY motif moves
away by approximately 0.5 Å in the N782.50 structure and the
position of residue N3017.49 rotates away by about 0.3 Å. This
conformational change may inﬂuence receptor signaling by dis-
rupting interactions required for activation26. In contrast, the
interaction between D/N782.50 and S1193.39, which is thought to
be important for the allosteric modulation of many class A
GPCRs17,27, is relatively weak in the two NK1R structures (3.8 Å
for the N782.50 and 3.3 Å for the D782.50 structures), suggesting
that S1193.39 may play a less critical role in NK1R activation.
Compared to another recently solved NK1R structure with glu-
tamic acid at 2.50 position28, the side chain of E2.50 further
extends toward the N3017.49 and further away from S1193.39, in
agreement with our speculation.
NK1R signals efﬁciently through Gq, Gs, and β-arrestin when
stimulated by SP29,30. It has been demonstrated that mutation of
the 2.50 residue greatly affects NK1R signal transduction17. Our
results of cell signaling assay indicate that mutations E782.50D
and E782.50N do not inﬂuence basal activity of NK1R
(Supplementary Figure 2 and Supplementary Figure 3). To
further understand the role of the hydrogen-bond interaction
between the residues at positions 2.50 and 7.49 in receptor
activation, we performed cAMP and inositol phosphate (IP)
accumulation assays for the NK1R mutants E782.50D, E782.50N,
N3017.49Q, N3017.49E, E782.50D/N3017.49Q, and E782.50N/
N3017.49E without any fusion partner, as it would block the G
protein binding and the receptor could not be activated (Fig. 3b,
c, Supplementary Figure 2, Supplementary Figure 3, Supplemen-
tary Table 2 and Supplementary Table 3). Our data show that
mutant E782.50D retained the ability of stimulating SP-induced Gs
and Gq signaling as seen with the wild-type receptor, while
mutant N3017.49Q exhibited reduced Gs and Gq responses to SP.
In contrast to the two single-residue mutations, the double
mutation E782.50D/N3017.49Q, which may beneﬁt from the
recovery of the hydrogen-bond interaction, preserved both Gs-
and Gq-mediated signaling. The differences in the G protein
signaling could be due to either direct inﬂuences of different
mutants or lower surface expression caused by the disruption of
ground state interactions of these mutants, which in turn alters
the observed signaling. These results indicate that hydrogen-bond
interactions between helices II and VII are required for receptor
activation. Similarly, the other single mutations, E782.50N and
N3017.49E, caused severe loss of the SP-induced Gs and Gq
signaling, while the double mutant E782.50N/N3017.49E restored
downstream cAMP and IP accumulation levels (to 50–80%) when
compared to the wild-type receptor.
19F-NMR studies of aprepitant bound to NK1R. To investigate
the dynamics of NK1R and characterize the binding mode of
aprepitant in solution, we acquired 19F-NMR spectra of the
ligand in the free-state as well as bound to NK1R variants with
different mutations at the 2.50 position. In the n-dodecyl-β-D-
maltopyranoside (DDM)/cholesteryl hemisuccinate (CHS)
detergent buffer used to solubilize NK1R, aprepitant showed two
ﬂuorine signals at −62.6 ppm (M) and −113.1 ppm (A), corre-
sponding to the two triﬂuoromethyl groups and the single aro-
matic 19F atom, respectively (Fig. 4e, j and Supplementary
Table 4). For aprepitant bound to NK1R, the triﬂuoromethyl
resonance was split into two peaks, P1 centered at −61.6 ppm,
and P2 at −63.0 ppm, both showing further ﬁne structures
(Fig. 4a–d). P1 and P2 correspond to the two triﬂuoromethyl
groups, and the chemical shifts reﬂect the different micro-
environments in the NK1R binding sites (Fig. 2). Lorentzian
deconvolution shows that P1 and P2 each contain two compo-
nents in all four complexes, and that a peak M from aprepitant
bound to excess micelles overlaps with P2 (Supplementary Fig-
ure 4). In all four complexes, there are thus two different substates
of the bound aprepitant (Fig. 4). Based on ring current shift
calculations using the crystal structure31,32, we assigned the peak
P1 to the ﬂuorine atoms FAD, FAE, and FAF, and peak P2 to
FAI, FAG, and FAH (Supplementary Figure 5 and Supplementary
Table 4). Major contributions to the ring current shifts came from
the NK1R residues W2616.48, F2646.51 and F2686.55, demon-
strating that the ligand-receptor interactions in the crystal
structure and in solution are closely related. Variable chemical
shift dispersion between P1 and P2 in the different mutants
(Fig. 4a–d) shows that there are conformational differences in the
binding site. When the mutation E782.50D was introduced, the
ﬂuorine peaks P2a and P2b (−63.1 and −62.9 ppm, respectively)
remained separated. For the E782.50N mutant, the two peaks P2a
and P2b merged accidentally into a single peak, while the peaks
P1a and P1b remained separated. These data suggest that the
ligand-binding pose preference is critically dependent on the
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Fig. 3 Interaction modes of the residues at positions 2.50 and 7.49 and functional assays of NK1R mutants. a Strong hydrogen-bond interaction between
D782.50 and N3017.49 (2.8 Å) and weak interaction between N782.50 and N3017.49 (3.5 Å). Two NK1R structures are shown in cartoon representation and
colored green (E782.50D mutant) and cyan (E782.50N mutant). The residues at positions 2.50 and 7.49 are shown as sticks. b SP-induced cAMP
accumulation measurements of the wild-type (WT) NK1R and the mutants E782.50D, N3017.49Q, E782.50D/N3017.49Q, E782.50N, N3017.49E, and
E782.50N/N3017.49E. Dose–response curves were generated from at least three independent experiments performed in triplicate. Data shown are mean ±
s.e.m. See Supplementary Table 3 for detailed statistical evaluation. c SP-induced IP1 accumulation of the WT NK1R and the mutants E782.50D, N3017.49Q,
E782.50D/N3017.49Q, E782.50N, N3017.49E, and E782.50N/N3017.49E. Dose–response curves were generated from at least three independent experiments
performed in triplicate or duplicate. Data shown are mean ± s.e.m. See Supplementary Table 2 for detailed statistical evaluation. Source data for Fig. 3b, c
are provided as a Source Data ﬁle
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residue in position 2.50. This correlates with our cAMP and IP1
accumulation assay results, which show that the E782.50N repla-
cement has a larger impact on receptor signaling than the
E782.50D mutation.
The presence of the separate peaks P1a, P1b, P2a, and P2b
implies that the corresponding conformational substates
exchange slowly on the chemical shift time scale31. To explore
possible differences among the conformational exchange rates in
the different proteins, we subsequently conducted two-
dimensional (2D) [19F, 19F]-EXSY experiments (Fig. 4k–n). The
presence of cross peaks between the components a and b of
P2 shows that the exchange between these two conformational
substates in the binding site has a rate in the millisecond range.
This is clearly displayed in Fig. 4k–n, whereas the separation of
the peaks a and b in P1 is too small to enable a detailed analysis.
The absence of cross peaks between P1 or P2 and M indicates that
the exchange between free and receptor-bound aprepitant is too
slow to be seen with current measurements, with kex ≤ 10 s−1 or
possibly orders of magnitude slower. The absence of cross peaks
between P1 and P2 shows that under the present experimental
conditions, the bis-triﬂuoromethyl-phenylethoxy moiety did not
undergo ring ﬂipping motions31, suggesting that the ligand-
binding site environment imposes a high-energy barrier to such
mobility.
Discussion
The crystal structure of NK1R bound to aprepitant provides a
detailed static picture of how the receptor interacts with its
antagonist. Overall, 15 residues are involved in the binding of
aprepitant, of which 10 are highly conserved across the neuro-
kinin receptor subfamily (Supplementary Figure 6). However, the
key residue F2646.51, which, to our knowledge, is not known to
be involved in the ligand binding of NK1R, is presented as tyr-
osine in NK2R and NK3R33. In the NK1R structure, the residue
F2646.51 forms a strong edge–π interaction with the bis-
triﬂuomethyl-phenyl ring of aprepitant, and the substitution of
the phenyl group with the phenolic group may disrupt the
interaction and cause a spatial clash with the ligand. Indeed,
aprepitant and its analogs possess a 1000-fold higher selectivity
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Fig. 4 19F NMR studies of aprepitant bound to NK1R in solution. a–j 1D 19F-NMR spectra of aprepitant in complex with different NK1R mutants and
aprepitant in the DDM/CHS detergent buffer. a–e Spectral region showing the resonances of the triﬂuoromethyl groups of the bis-triﬂuoromethyl-
phenylethoxy moiety; f–j Spectral region of the 4-ﬂuorophenyl moiety. k–n, 2D [19F,19F]-EXSY spectra recorded with a mixing time of 150ms covering the
same spectral region as panels a–d
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08568-5 ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:638 | https://doi.org/10.1038/s41467-019-08568-5 | www.nature.com/naturecommunications 5
towards NK1R over NK2R and NK3R despite their highly con-
served ligand-binding pockets10,25. When F2646.51Y was intro-
duced, the inhibition in Gq signaling of NK1R by aprepitant was
signiﬁcantly decreased (Supplementary Table 2). Besides F2646.51,
E1935.35, and I2045.46, which form a hydrogen bond or hydro-
pobic interactions with aprepitant, are also not conserved among
the neurokinin receptors (Supplementary Figure 4). This residue
may contribute to ligand selectivity within the neurokinin
receptor family. Thus, insights gained from the NK1R–aprepitant
complex structures will greatly facilitate the development of more
selective drug leads by targeting the variable regions of the ligand-
binding pocket and enhancing interactions with corresponding
residues.
Conserved residues at the allosteric interface between positions
2.50, 3.39, and 7.49 form a complex water hydrogen-bond net-
work, thereby ﬁne-tuning the 7TM conformation of GPCRs17.
This network is gated by two conserved residues: W6.48 in the
CWxP6.50 motif of helix VI within the ligand-binding pocket and
Y7.53 in the NP7.50 xxY motif of helix VII on the intracellular side
of the receptor. Comparing the NK1R structures with different
mutations at position 2.50, we observed structural differences in
the helical bundle around W6.48 and Y7.53 region, especially in the
NPxxY motif, suggesting that the conserved residue E2.50 may
regulate receptor signaling via the hydrogen-bond network of this
region. In addition, a dynamic perspective from NMR data
demonstrates that aprepitant displays slightly different binding
modes between the two NK1R structures, suggesting that ligand
could adopt multiple poses in NK1R, which might be further
regulated by this hydrogen-bond network. The previously
reported fact that alanine substitutions of residues, such as E2.50
and N7.49, increased the constitutive activity Gs but not Gq sig-
naling17 is in line with our NMR results showing that only certain
receptor conformations were affected by mutations of these
residues. Our results imply that even though different G protein
subtypes share similar structure scaffold, their activation requires
a different receptor conformation that is regulated by this
hydrogen-bond network. Previous research has shown that the
residue at position 2.50 is very important for GPCR signaling15–17
and that its mutation to asparagine eliminates the downstream
signals on several GPCRs18,19. Our observations of conforma-
tional changes in the NK1R structures, which are consistent with
these reports, together indicate that this hydrogen-bond network
may play a key role in receptor activation and is valuable for
deepening the understanding of the drug action.
Methods
Cloning of the NK1R receptor. The codon-optimized human NK1R gene
(sequence is shown in Supplementary Table 5) was cloned into a modiﬁed
pFastBac1 vector (Invitrogen) containing an expression cassette with a hae-
magglutinin signal sequence and a Flag tag at the N terminus and a PreScission
protease site followed by a 10× His-tag at the C terminus. To facilitate crystal-
lization, a modiﬁed T4 lysozyme (mT4L)34 protein was inserted between the
residues S226 and H237 in the third intracellular loop (ICL3) of NK1R and 72
residues (336–407) were removed at the C terminus (primer sequences are shown
in Supplementary Table 5). The NK1R-mT4L gene was further modiﬁed by
introducing four mutations based on literature:34 E782.50D, Q1654.60A, Y1213.41W,
and T2225.64R (construct NK1R-E782.50D) to improve the protein yield by over
twofolds and the protein melting temperature by ~10°. Another NK1R construct
NK1R-E782.50N was generated by switching the mutation E782.50D to E782.50N
and removing the Q1654.60A mutation.
Expression and puriﬁcation. High-titer recombinant baculovirus (>108 viral
particles per ml) was obtained using the Bac-to-Bac Baculovirus Expression System
(Invitrogen). Spodoptera frugiperda (Sf9) cells (Invitrogen) at a cell density of
2–3 × 106 cells ml−1 were infected with the virus at a multiplicity of infection of 5.
Cells were routinely tested for mycoplasma contamination. Cells were harvested by
centrifugation 48 h post-infection and stored at −80 °C until use. Insect cell
membranes were disrupted by thawing frozen cell pellets in a hypotonic buffer
containing 10 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM KCl, and EDTA-free
protease inhibitor cocktail (Roche) at the ratio of 1 tablet per 100 ml buffer. After
centrifugation (45Ti rotor, Optima L90K, Beckman) at 125,000×g for 30 min at
4 °C, the membranes were further prepared with two washes using a high-osmotic
buffer containing 10 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM KCl, and 1M
NaCl, and one more wash with the hypotonic buffer to remove the high con-
centration of NaCl. The puriﬁed membranes were then resuspended in the
hypotonic buffer supplemented with 20% glycerol, ﬂash-frozen in liquid nitrogen,
and stored at −80 °C until use.
Puriﬁed membranes were thawed on ice in the presence of 100 µM aprepitant,
2 mgml−1 iodoacetamide and EDTA-free protease inhibitor cocktail (Roche), and
incubated at 4 °C for 1 h. The membranes were then solubilized in 50 mM HEPES
pH 7.5, 10% glycerol, 500 mM NaCl, 0.5% (w/v) (DDM, Affymetrix), 0.1% (w/v)
CHS (Sigma), and 50 µM aprepitant. After incubation at 4 °C for 3 h, the
supernatant was isolated by centrifugation (70Ti rotor, Optima L90K, Beckman) at
125,000×g for 30 min, supplemented with imidazole to a ﬁnal concentration of 10
mM, and incubated with TALON IMAC resin (Clontech) overnight at 4 °C. The
resin was washed with ﬁve column volumes of wash buffer containing 25 mM
HEPES, pH 7.5, 500 mM NaCl, 10% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v)
CHS, 30 mM imidazole, and 50 µM aprepitant, and then incubated in a Lauryl
maltose-neopentyl glycol (LMNG)-exchange buffer containing 25 mM HEPES, pH
7.5, 500 mM NaCl, 10% (v/v) glycerol, 0.5% (w/v) LMNG (Affymetrix), 0.01% (w/
v) CHS, 30 mM imidazole, and 50 µM aprepitant at 4 °C for 2 h. After washing with
ﬁve column volumes of wash buffer, the resin was further incubated in a DDM-
exchange buffer containing 25 mM HEPES, pH 7.5, 500 mM NaCl, 10% (v/v)
glycerol, 0.5% (w/v) DDM, 0.01% (w/v) CHS, 30 mM imidazole, and 50 µM
aprepitant at 4 °C for 1 h. Further washes were carried out with eight column
volumes of wash buffer. The NK1R sample was then eluted with ﬁve column
volumes of elute buffer containing 25 mM HEPES, pH 7.5, 500 mM NaCl, 10% (v/
v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 300 mM imidazole, and 50 µM
aprepitant. A PD MiniTrap G-25 column (GE Healthcare) was used to remove
imidazole. The receptor was then treated overnight with His-tagged PreScission
protease (custom-made) and His-tagged PNGase F (custom-made) to remove the
C-terminal His-tag and deglycosylate protein. The protein was subsequently
incubated with Ni-NTA resin (Qiagen) at 4 °C for 1 h to remove the cleaved His-
tag, PreScission protease and PNGase F. The puriﬁed NK1R-aprepitant complex
was concentrated to 40 mgml−1 with a 100 kDa molecular weight cut-off
concentrator (Millipore). Protein purity and monodispersity were tested by sodium
dodecyl sulfate polyacrylamide gel electrophoresis and analytical size-exclusion
chromatography (aSEC). Typically, the protein purity was over 95% and the aSEC
proﬁle showed a single peak, an indication of receptor monodispersity.
Lipidic cubic phase crystallization. The NK1R–aprepitant complex was crys-
tallized using the lipidic cubic phase (LCP) method by mixing the protein sample
(~40 mg ml−1) with lipid (monoolein and cholesterol 10:1 by mass) at weight
ratio of 2:3 using a mechanical syringe mixer until a homogenous mesophase
was achieved35. The LCP mixture was then dispensed onto glass sandwich plates
(Shanghai FAstal BioTech) in 40 nl drops and overlaid with 800 nl precipitant
solution using a Gryphon LCP robot (Bioray GP17, ARI). Protein reconstitution
in LCP and crystallization trials were performed at room temperature
(19–22 °C). Crystals appeared after 3 days and reached their full size within
2 weeks in 0.1 M MES, pH 6.0–6.6, 25–35% PEG400, 200–350 mM ammonium
tartrate dibasic, and 50 μM aprepitant. Crystals were harvested directly from
LCP using 50–75 μm micro-loops (M2-L19-50/75, MiTeGen) and ﬂash frozen in
liquid nitrogen.
Data collection and structure resolution. X-ray diffraction data were collected
using a Pilatus3 6M detector (X-ray wavelength 1.0000 Å) at the SPring-8 beam-
line 41XU, Hyogo, Japan. The crystals were exposed with a 10 µm × 8 µm mini-
beam for 0.2 s and 0.2° oscillation per frame. A raster system was used to ﬁnd the
best-diffracting parts of single crystals36. Most crystals of NK1R-E782.50D-
aprepitant diffracted to 3.3–3.0 Å resolution and most crystals of NK1R-E782.50N-
aprepitant diffracted to 3.2–2.7 Å resolution. Data from the 47 best-diffracting
crystals of NK1R-E782.50D-aprepitant were integrated and scaled at 3.2 Å resolu-
tion using XDS37. Data from the 21 best-diffracting crystals of NK1R-E782.50D-
aprepitant were integrated and scaled at 2.7 Å resolution. Both datasets were fur-
ther truncated using UCLA anisotropy server (http://services.mbi.ucla.edu/
anisoscale) to remove anisotropy issues. Initial phase information was obtained by
molecular replacement using the program Phaser38 with the receptor portion of
NTSR1 (PDB accession code: 4GRV) and the mT4L in the M3 structure (PDB
accession code: 4U15) as templates. Reﬁnement was performed with REFMAC539
and BUSTER40 followed by manual examination and rebuilding of the reﬁned
coordinates in the program COOT41 using both ∣2Fo∣− ∣Fc∣ and ∣Fo∣− ∣Fc∣ maps.
The Ramachandran plot analysis indicates that 100% of the residues are in
favorable (NK1-E782.50D-aprepitant, 94.9%; NK1-E782.50N-aprepitant, 96.2%) or
allowed (NK1-E782.50D-aprepitant, 5.1%; NK1-E782.50N-aprepitant, 3.8%) regions
(no outliers). The ﬁnal models of NK1R-E782.50D-aprepitant and NK1R-E782.50N-
aprepitant include 286 residues (F25-S226 and H237-R321) of NK1R and residues
N1-E10 and A17-Y117 of mT4L. The remaining N- and C-terminal residues were
disordered and not reﬁned.
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NMR spectroscopy. NMR samples were prepared using a similar procedure as for
the crystallographic studies, except that the concentration of NaCl was lowered to
300 mM and no additional aprepitant or glycerol was added during the wash and
elusion steps. 19F-NMR spectra of protein samples with a ﬁnal concentration of 2
mgml−1 were measured with a Bruker AVANCE 600 spectrometer at 25 °C, using
a TCI 1H/19F–13C–15N triple resonance cryoprobe. The 19F chemical shifts were
calibrated relative to triﬂuoroacetic acid (TFA) at −75.5 ppm. 1D 19F-NMR spectra
were recorded with 16k complex points, which were zero-ﬁlled to 32k points; the
relaxation delay was 1 s.
2D [19F,19F]-EXSY experiments were recorded with 2k and 32 complex points
in the direct and indirect dimensions, respectively. The mixing time was 150 ms.
The data were zero-ﬁlled to 4k and 64 points in the direct and indirect dimensions.
The line-broadening factor of the EM function was 30 Hz.
cAMP and IP1 assays. Flag-tagged wild-type and mutant NK1Rs were cloned into
the expression vector pcDNA3.1/V5-His-TOPO (Invitrogen) and expressed in
HEK293 cells (ATCC). Cells were routinely tested for mycoplasma contamination.
Cells were harvested 48 h post-transfection. To measure cell-surface expression of
the NK1 receptors, 10 μl cells were mixed with 15 μl Monoclonal ANTI-FLAG M2-
FITC antibody (Sigma, F4049; 1:100 diluted by TBS supplemented with 4% BSA).
After a 20-min reaction, the ﬂuorescence of the bound antibody was measured by
an FCM (Flow Cytometry) reader (Millipore).
cAMP accumulation was measured using a cAMP kit (Cisbio Bioassays,
62AM4PEB). The harvested cells were plated into 384-well plates (6000 cells per
well) and treated with different concentrations of SP (1 pM–10 μM) diluted in
Dulbecco’s Modiﬁed Eagle Medium (DMEM) supplemented with 0.1% BSA at
37 °C for 30 min. Then cryptate-labeled anti-cAMP monoclonal antibody and d2-
labeled cAMP in Lysis Buffer were added to the wells. After a 1-h incubation at
room temperature, plates were read in an EnVision multilabel plate reader
(PerkinElmer) with excitation at 320 nm and emission at 620 and 665 nm. The
accumulation of cAMP was calculated according to a standard dose–response
curve.
IP1 accumulation was measured using an IP1 kit (Cisbio Bioassays, 62IPAPEB).
The harvested cells were plated into 384-well plates (6000 cells per well) and treated
with different concentrations of SP (10 pM–100 μM) diluted in DMEM
supplemented with 0.1% BSA at 37 °C for 30 min. For the aprepitant competition
assays, an additional 100 nM aprepitant was added and co-incubated with SP at
37 °C for 30 min. Then cryptate-labeled anti-IP1 monoclonal antibody and d2-
labeled IP1 in Lysis Buffer were added to the wells. After 1 h incubation at room
temperature, plates were read in an EnVision multilabel plate reader (PerkinElmer)
with excitation at 320 nm and emission at 620 nm and 665 nm. The accumulation
of IP1 was calculated according to a standard dose–response curve using GraphPad
Prism 5.0 (GraphPad Software). The curves were normalized to the top (100%) and
bottom (0%) values of the associated NK1R curve. Using nonlinear regression
(curve ﬁt) the EC50 and pEC50 ± S.E.M. were calculated.
Data availability
Atomic coordinates and structure factors of NK1R (E2.50N)-aprepitant and NK1R
(E2.50D)-aprepitant complex structures have been deposited in the Protein Data Bank
with accession codes 6J20 and 6J21. The source data underlying Fig. 3b, c and Supple-
mentary Figs. 2 and 3 are provided as a Source Data ﬁle. Other data are available from
the corresponding authors upon reasonable request.
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